Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04917861 · ClinicalTrials.gov registry record · Phase 2

A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas

A Phase 2 study of Zika Virus, sponsored by ModernaTX.

Completed
Registry status
Phase 2
Development phase
808
Enrollment target
11
Study locations

NCT04917861 is a Phase 2 study of Zika Virus that has completed, run by ModernaTX. The registered enrollment target is 808 participants, above the 173-participant average among 3 other Zika Virus trials with a reported enrollment target (367% higher). The trial reports 11 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04917861, a Phase 2 study of Zika Virus, has completed, sponsored by ModernaTX.

COMPLETED
Registry status
Phase 2
Development phase
808 participants
Enrollment target
11
Study locations

Study Summary

This clinical study will evaluate the safety, tolerability, and reactogenicity of 2 dose levels of messenger RNA (mRNA)-1893 Zika vaccine in comparison to a placebo control in healthy participants who are flavivirus-seronegative and in participants who are flavivirus-seropositive.

Conditions Studied

Zika Virus

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL mRNA-1893

Study Locations (11)

PR

  • Clinical Research Puerto Rico, Inc. - Guayama
  • Ponce Medical School Foundation, Inc. - Ponce
  • Ponce Medical School Foundation, Inc. - Ponce
  • Clinical Research Puerto Rico, Inc. - San Juan
  • Latin Clinical Trial Center, Inc. - San Juan
  • GCM Medical Group, PSC - San Juan
  • Carribean Medical Research - San Juan
  • University of Puerto Rico - San Juan

Iowa

  • Meridian Clinical Research (Sioux City, IA) - Sioux City

Kansas

  • Johnson County Clin-Trials - Lenexa

Texas

  • Benchmark Research - Fort Worth - Fort Worth

Trial Details

FieldValue
Enrollment Target 808 participants
Start Date 2021-06-07
Est. Completion 2024-07-26
Phase Phase 2

Sponsor

ModernaTX

90 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04917861

The ClinicalTrials.gov registry entry for NCT04917861 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 808 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 173-participant average among 3 other Zika Virus trials with a reported enrollment target (367% higher). The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Zika Virus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04917861 reports 11 study locations spanning 4 distinct geographic areas - top geographies include PR, Iowa, Kansas.

Frequently Asked Questions

What is clinical trial NCT04917861 about?

NCT04917861 is a clinical study titled "A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas". This clinical study will evaluate the safety, tolerability, and reactogenicity of 2 dose levels of messenger RNA (mRNA)-1893 Zika vaccine in comparison to a placebo control in healthy participants who are flavivirus-seronegative and in participants who are flavivirus-seropositive.

What is the current status of trial NCT04917861?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 808 participants. The study started on 2021-06-07. Estimated completion is 2024-07-26.

What conditions does trial NCT04917861 study?

This clinical trial studies the following conditions: Zika Virus.

What interventions are being tested in trial NCT04917861?

The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1893 (BIOLOGICAL).

Who is sponsoring clinical trial NCT04917861?

This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04917861 being conducted?

This trial has 11 study locations across Iowa, Kansas, Texas, PR. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Zika Virus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Zika Virus

All registered trials for this condition

Iowa

All trials with a study site in Iowa

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.